Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum

John T. Sandlund, Michael Martin

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The non-Hodgkin lymphomas (NHLs) occurring in children and adolescents and young adults (AYA) are characterized by various age-related differences in tumor biology and survival. Children generally present with high-grade lymphomas, such as Burkitt lymphoma, diffuse large B-cell lymphoma, lymphoblastic lymphoma, and anaplastic large cell lymphoma, whereas low-grade histologic subtypes, such as follicular lymphoma, occur more frequently with increasing age. Treatment outcome for children with NHL is generally superior to that observed in adults. Factors contributing to this discrepancy include psychosocial factors, patient factors, and differences in tumor biology and therapy. These factors will be reviewed, with particular attention to the biological features of diffuse large B-cell lymphoma and anaplastic large cell lymphoma and corresponding therapeutic challenges. Novel targeting agents have been developed, which have been shown to be active in some patients. There is clearly a need for treatment protocols with eligibility criteria that cover the full span of the pediatric and AYA age range and that incorporate detailed molecular characterization of the tumors.

Original languageEnglish (US)
Pages (from-to)589-597
Number of pages9
JournalHematology
Volume2016
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Non-Hodgkin's Lymphoma
Anaplastic Large-Cell Lymphoma
Young Adult
Lymphoma, Large B-Cell, Diffuse
Pediatrics
Neoplasms
Follicular Lymphoma
Burkitt Lymphoma
Clinical Protocols
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Psychology
Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Medicine(all)

Cite this

Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum. / Sandlund, John T.; Martin, Michael.

In: Hematology, Vol. 2016, No. 1, 01.01.2016, p. 589-597.

Research output: Contribution to journalArticle

@article{fd6cca72eb0f444ba0025c41a129dd45,
title = "Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum",
abstract = "The non-Hodgkin lymphomas (NHLs) occurring in children and adolescents and young adults (AYA) are characterized by various age-related differences in tumor biology and survival. Children generally present with high-grade lymphomas, such as Burkitt lymphoma, diffuse large B-cell lymphoma, lymphoblastic lymphoma, and anaplastic large cell lymphoma, whereas low-grade histologic subtypes, such as follicular lymphoma, occur more frequently with increasing age. Treatment outcome for children with NHL is generally superior to that observed in adults. Factors contributing to this discrepancy include psychosocial factors, patient factors, and differences in tumor biology and therapy. These factors will be reviewed, with particular attention to the biological features of diffuse large B-cell lymphoma and anaplastic large cell lymphoma and corresponding therapeutic challenges. Novel targeting agents have been developed, which have been shown to be active in some patients. There is clearly a need for treatment protocols with eligibility criteria that cover the full span of the pediatric and AYA age range and that incorporate detailed molecular characterization of the tumors.",
author = "Sandlund, {John T.} and Michael Martin",
year = "2016",
month = "1",
day = "1",
doi = "10.1182/asheducation-2016.1.589",
language = "English (US)",
volume = "2016",
pages = "589--597",
journal = "Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program",
issn = "1520-4391",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum

AU - Sandlund, John T.

AU - Martin, Michael

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The non-Hodgkin lymphomas (NHLs) occurring in children and adolescents and young adults (AYA) are characterized by various age-related differences in tumor biology and survival. Children generally present with high-grade lymphomas, such as Burkitt lymphoma, diffuse large B-cell lymphoma, lymphoblastic lymphoma, and anaplastic large cell lymphoma, whereas low-grade histologic subtypes, such as follicular lymphoma, occur more frequently with increasing age. Treatment outcome for children with NHL is generally superior to that observed in adults. Factors contributing to this discrepancy include psychosocial factors, patient factors, and differences in tumor biology and therapy. These factors will be reviewed, with particular attention to the biological features of diffuse large B-cell lymphoma and anaplastic large cell lymphoma and corresponding therapeutic challenges. Novel targeting agents have been developed, which have been shown to be active in some patients. There is clearly a need for treatment protocols with eligibility criteria that cover the full span of the pediatric and AYA age range and that incorporate detailed molecular characterization of the tumors.

AB - The non-Hodgkin lymphomas (NHLs) occurring in children and adolescents and young adults (AYA) are characterized by various age-related differences in tumor biology and survival. Children generally present with high-grade lymphomas, such as Burkitt lymphoma, diffuse large B-cell lymphoma, lymphoblastic lymphoma, and anaplastic large cell lymphoma, whereas low-grade histologic subtypes, such as follicular lymphoma, occur more frequently with increasing age. Treatment outcome for children with NHL is generally superior to that observed in adults. Factors contributing to this discrepancy include psychosocial factors, patient factors, and differences in tumor biology and therapy. These factors will be reviewed, with particular attention to the biological features of diffuse large B-cell lymphoma and anaplastic large cell lymphoma and corresponding therapeutic challenges. Novel targeting agents have been developed, which have been shown to be active in some patients. There is clearly a need for treatment protocols with eligibility criteria that cover the full span of the pediatric and AYA age range and that incorporate detailed molecular characterization of the tumors.

UR - http://www.scopus.com/inward/record.url?scp=85020250505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020250505&partnerID=8YFLogxK

U2 - 10.1182/asheducation-2016.1.589

DO - 10.1182/asheducation-2016.1.589

M3 - Article

VL - 2016

SP - 589

EP - 597

JO - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

JF - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

SN - 1520-4391

IS - 1

ER -